$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Where can I buy Rybrevant? What is the dosage of Rybrevant?
2025-10-19 11:44:20
Check Details
Can dacomitinib be reimbursed by medical insurance? What should I pay attention to?
2025-10-19 11:44:20
Check Details
FDA announces that Rybrevant, the first targeted drug for lung cancer EGFR20ins, has been approved for marketing
2025-10-19 11:44:20
Check Details
How to use Rybrevant? How long does it take for resistance to develop?
2025-10-19 11:44:20
Check Details
Where can I buy the third-generation ALK inhibitor lorlatinib? What is the effect?
2025-10-19 11:44:20
Check Details
What is the dosage of lorlatinib? What are the side effects?
2025-10-19 11:44:20
Check Details
Targeted drug treatment of EGFR gene mutation lung cancer (1)
2025-10-19 11:44:20
Check Details
Lumakras (AMG510) was approved for marketing - breaking through the milestone of "undruggable" KRAS
2025-10-19 11:44:20
Check Details
FDA approves Amgen’s Lumakras: the world’s first KRAS-targeted therapy!
2025-10-19 11:44:20
Check Details
Detailed survival data and side effects of Lorlatinib!
2025-10-19 11:44:20
Check Details
How about the effect of AMG510 (Lumakras)? Where can I buy it in China?
2025-10-19 11:44:20
Check Details
What is the dosage of crizotinib? How long does it take for the side effects of crizotinib to disappear?
2025-10-19 11:44:20
Check Details
1
2
...
3978
3979
3980
3981
3982
3983
3984
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
2
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
3
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
4
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
5
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
6
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
7
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
8
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
9
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
10
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
11
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
12
Vemurafenib (Zelboraf) Complete Medication Guide